Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
KALA logo KALA
Upturn stock ratingUpturn stock rating
KALA logo

Kala Pharmaceuticals Inc (KALA)

Upturn stock ratingUpturn stock rating
$4.76
Last Close (24-hour delay)
Profit since last BUY10.7%
upturn advisory
Consider higher Upturn Star rating
BUY since 11 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: KALA (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $13.5

1 Year Target Price $13.5

Analysts Price Target For last 52 week
$13.5Target price
Low$2.92
Current$4.76
high$11.2

Analysis of Past Performance

Type Stock
Historic Profit -29.81%
Avg. Invested days 20
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 29.81M USD
Price to earnings Ratio -
1Y Target Price 13.5
Price to earnings Ratio -
1Y Target Price 13.5
Volume (30-day avg) 2
Beta -1.98
52 Weeks Range 2.92 - 11.20
Updated Date 06/30/2025
52 Weeks Range 2.92 - 11.20
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -7.36

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -48.51%
Return on Equity (TTM) -576.46%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 19169243
Price to Sales(TTM) 1.16
Enterprise Value 19169243
Price to Sales(TTM) 1.16
Enterprise Value to Revenue 0.04
Enterprise Value to EBITDA -0.16
Shares Outstanding 6452400
Shares Floating 3685223
Shares Outstanding 6452400
Shares Floating 3685223
Percent Insiders 2.11
Percent Institutions 64.18

Analyst Ratings

Rating 2
Target Price 13.5
Buy 1
Strong Buy 1
Buy 1
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Kala Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Kala Pharmaceuticals, Inc. was a biopharmaceutical company focused on the development and commercialization of innovative therapies for eye diseases. Founded in 2009, it aimed to improve treatment paradigms for both front and back of the eye indications. Significant milestones included FDA approvals for its products. It has since ceased operations and liquidation is in progress.

business area logo Core Business Areas

  • Pharmaceutical Development and Commercialization: Focused on researching, developing, and commercializing therapies for ocular diseases, particularly those affecting the front and back of the eye.

leadership logo Leadership and Structure

Historically, Kala Pharmaceuticals had a CEO and a management team overseeing its operations. Details of the specific leadership team are not relevant as the company is ceasing operations.

Top Products and Market Share

overview logo Key Offerings

  • Inveltys (loteprednol etabonate ophthalmic suspension) 1%: Indicated for the treatment of post-operative inflammation and pain following ocular surgery. Market share data unavailable due to the company ceasing operations. Competitors included other steroidal and non-steroidal anti-inflammatory drugs for post-operative inflammation, such as those from Allergan (now AbbVie) and Novartis.
  • Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25%: Indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. Market share data unavailable due to the company ceasing operations. Competitors included Restasis and Xiidra and other dry eye treatments from companies like Novartis and Allergan (now AbbVie).

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, specifically in ophthalmology, is characterized by significant competition and a focus on developing innovative treatments for various eye diseases. There is high demand due to the aging population and prevalence of conditions like dry eye and glaucoma.

Positioning

Historically, Kala Pharmaceuticals positioned itself as a developer of differentiated ophthalmic therapies using its proprietary mucus-penetrating particle (MPP) technology. Its ceased operations meant their position is no longer active.

Total Addressable Market (TAM)

The global ophthalmic drug market is substantial, reaching billions of dollars annually. Kala Pharmaceuticals aimed to capture a portion of this market with its products, but the company's ceased operations impacts it's market reach.

Upturn SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Competitors and Market Share

competitor logo Key Competitors

  • ABBV
  • NVS

Competitive Landscape

Kala Pharmaceuticals faced intense competition from larger, established pharmaceutical companies with broader portfolios and greater resources. Its ceased operations reflects its inability to compete effectively in the long term.

Growth Trajectory and Initiatives

Historical Growth: Kala Pharmaceuticals had revenue growth periods following FDA approvals, but the company ultimately faced financial challenges and ceased operations.

Future Projections: There are no future growth projections due to the company ceasing operations.

Recent Initiatives: Recent initiatives included cost-cutting measures and attempts to secure financing, which ultimately failed to prevent the company's closure.

Summary

Kala Pharmaceuticals, once a promising biopharmaceutical company, ultimately failed to achieve sustainable profitability and ceased operations. Its core products, Inveltys and Eysuvis, faced significant competition. The company's struggles highlight the challenges of developing and commercializing ophthalmic therapies. Investors should be aware that KALA stock is no longer an active security.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Press Releases
  • Industry Reports
  • Company website archives

Disclaimers:

This analysis is based on publicly available information and historical data. The information is provided for informational purposes only and should not be considered financial advice. As the company has ceased operations, the information is for historical purposes only and should not be used to make investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Kala Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Arlington, MA, United States
IPO Launch date 2017-07-20
Interim CEO, President & COO Mr. Todd Bazemore
Sector Healthcare
Industry Biotechnology
Full time employees 38
Full time employees 38

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.